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Abstract.
Background: Bladder Cancer (BC) has two clearly distinct phenotypes. Non-muscle invasive BC has good prognosis and is
treated with tumor resection and intravesical therapy whereas muscle invasive BC has poor prognosis and requires usually
systemic cisplatin based chemotherapy either prior to or after radical cystectomy. Neoadjuvant chemotherapy is not often used
for patients undergoing cystectomy. High-throughput analytical omics techniques are now available that allow the identification
of individual molecular signatures to characterize the invasive phenotype. However, a large amount of data produced by omics
experiments is not easily accessible since it is often scattered over many publications or stored in supplementary files.
Objective: To develop a novel open-source database, BcCluster (http://www.bccluster.org/), dedicated to the comprehensive
molecular characterization of muscle invasive bladder carcinoma.
Materials: A database was created containing all reported molecular features significant in invasive BC. The query interface was
developed in Ruby programming language (version 1.9.3) using the web-framework Rails (version 4.1.5) (http://rubyonrails.org/).
Results: BcCluster contains the data from 112 published references, providing 1,559 statistically significant features relative to
BC invasion. The database also holds 435 protein-protein interaction data and 92 molecular pathways significant in BC invasion.
The database can be used to retrieve binding partners and pathways for any protein of interest. We illustrate this possibility using
survivin, a known BC biomarker.
Conclusions: BcCluster is an online database for retrieving molecular signatures relative to BC invasion. This application offers
a comprehensive view of BC invasiveness at the molecular level and allows formulation of research hypotheses relevant to this
phenotype.
Keywords: Bladder cancer, protein interactome, biomarker, bioinformatics, survivin, data integration, relational database man-
agement system, web application framework
INTRODUCTION
Urothelial bladder carcinoma (BC) is a common
malignancy of the urinary tract system presenting
an estimate of 468,351 new bladder cancer cases
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and 179,753 deaths predicted for the year 2015
by the WHO GLOBOCAN (http://globocan.iarc.fr/
Default.aspx) [1, 2]. Albeit variable for individual
bladder cancer patients, initial symptoms include
hematuria and flank pain [3, 4]. Cystoscopy is the
gold standard diagnostic procedure with a reported
sensitivity of 62–84% and specificity of 43–98%.
This wide variability in sensitivity and specificity indi-
cates a significant inter-operator variability [5]. Non
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muscle-invasive BC (CIS, Ta, T1) is treated with
resection and intravesical therapy whereas muscle-
invasive tumors (T2, T3, T4) require radical cystec-
tomy usually combined with systemic cisplatin-based
chemotherapy [6–8]. Non-invasive BC comprises two
forms: papillary urothelial carcinoma (Ta) and car-
cinoma in-situ (CIS), both of which can progress to
invasive disease of the lamina propria (T1) or the detru-
sor muscle (T2) [6]. Muscle invasive tumors have been
distinguished into three distinct molecular subtypes,
basal, luminal, and “p53-like” [9, 10]. Another classi-
fication system for the molecular subtypes of muscle
invasive BC was carried out using data stored in The
Cancer Genome Atlas (TCGA) (http://cancergenome.
nih.gov/) and resulted in the report of four clusters
termed TCGA I, II, III, and IV as described by Wein-
stein JN et al. [11]. In addition, the Lund classification
reports six different BC molecular subtypes [12].
A recent review compares the different classifications
of muscle invasive BC subtypes and concludes muscle
invasive BC exhibits significant heterogeneity com-
pared to other tumor types [13]. Moreover, a recent
report highlights significant errors in clinical stag-
ing of patients with bladder cancer that underwent
cystectomy [14]. Obtaining an accurate staging diag-
nosis is particularly crucial in patient selection for
surgical treatments (i.e. cystectomy) and the choice
of chemotherapy. Due to the invasive procedure of
cystoscopy and in order to improve accuracy in the
phenotype detection, blood or urine biomarkers could
support clinical assessment [15]. Biomarkers mea-
sured at the DNA, RNA and/or protein levels provide
the potential to choose optimum surveillance measures
and treatment regimens for specific patient populations
[16]. A better understanding of muscle invasive BC
could be achieved by combining information obtained
from individual biomarkers. Such a comprehensive
view could help in predicting novel molecular targets
and improve disease management.
High-throughput experimental platform technolo-
gies range from genomic sequencing to epigenomic,
transcriptomic, proteomic and metabolomic profil-
ing to characterize the molecular aspects of clinical
phenotypes [17–24]. The advent of these approaches
that generate a comprehensive view of the molecu-
lar landscape for a biological sample has introduced
a paradigm shift in the way diseases are perceived
[17, 18, 25]. A variety of datasets for such charac-
terizations have become available for e.g. in Array
Express/Gene Expression Omnibus (GEO) for tran-
scriptomics, Human Proteinpedia for proteomics,
Human Protein Atlas (http://www.proteinatlas.org/)
for immunohistochemically validated proteins, or in
large data consolidation platforms such as GeneCards
[26]. In regard to disease specific omics data, valu-
able general sources in oncology include TCGA,
Oncomine [27], and Online Mendelian Inheritance
in Man (OMIM) [28]. The TCGA oncology por-
tal currently lists SNPs, methylation data, mutations,
mRNAs, miRNAs and proteins relevant to BC. A
recent report presents a systems biology approach for
the analysis of the MIBC dataset contained in TCGA
[11]. Another database for BC that provides molecular
features in regard to miRNAs identified in liter-
ature (http://bladder.pparser.net/MIRMarkers.php) is
also available [29, 30]. In addition, a user-friendly
tool called BC-BET is also available and allows the
evaluation of gene expression profiles determined by
microarray studies across bladder cancer patients [31].
Though omics profiling has provided an abundance
of data, technical boundaries involving incomplete-
ness of the individual molecular datasets together with
the static representation of cellular activity limit the
insights on molecular processes and their interaction
dynamics [32–34]. A large number of biological path-
way analysis tools are available, including KEGG [35],
PANTHER [36], REACTOME [37] and AmiGO [38]
described in PathGuide (http://www.pathguide.org/),
and allow detection of significant metabolic and
signaling pathways. Previous omics studies report
biomarkers associated with bladder cancer, and ther-
apeutic targets that could allow development of
personalized therapies [39–43].
Currently abundant datasets are readily available,
but the information gathered from these large number
of omics experiments is not fully exploited, as they are
either scattered in many publications and databases or
held in supplementary data files. In order to allow effi-
cient retrieval of information and offer a global view
of BC invasion at the molecular level, we developed
BcCluster an open-source Bladder Cancer database
(http://www.bccluster.org/).
The purpose of the publication is to describe the
database and offer an example on how it can be used in
the context of MIBC research with a specific example
of its application (survivin).
MATERIALS AND METHODS
Data sources for characterizing bladder cancer
pathophysiology
In order to retrieve molecular features associated
with muscle invasive bladder cancer, NCBI PubMed,
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Web of Science, Google Scholar and the omics repos-
itories Gene Expression Omnibus (GEO) [44] and
ArrayExpress [45] were queried. The keywords for the
literature search included “bladder OR urothelial OR
transitional cell” AND “neoplasm OR tumor OR car-
cinoma” AND “muscle” AND “invas* OR aggress*
OR progress* OR inflammation” (Database version
of June, 2015). The list of publications relevant to
muscle invasion in BC was isolated from the com-
plete list of retrieved papers. Publications were further
screened for adequacy in sample size (at least 50
samples included in study design), magnitude of dif-
ferential abundance (>2-fold change for proteomics,
transcriptomics, metabolomics and miRNAs), FDR
<0.1 for mutations, p values <0.05 for methylation and
–omics studies, in addition to the specific phenotypic
conditions; T2a/b, T3a/b, T4a/b. The MIBC-specific
molecular features retrieved from the publications
comprised of various sources such as DNA-mutations,
DNA-methylation, mRNAs, miRNAs, proteins (IHC
validated and proteomics) and metabolites. The fea-
tures were then combined for further systems biology
analysis.
Systems biology analysis – protein-protein
interactions (PPI) and pathway enrichment
For performing systems biology analysis that
includes integration of molecular features from various
resources, certain filtering steps for the total number
of features were taken into account. For the protein-
protein interaction and pathway enrichment analysis,
microRNA and metabolomic data, although they are
an integral part of the database, were not taken into
consideration (i.e. official gene symbols mapped from
metabolomics and miRNA data, by querying HMDB
and miRBase). This choice was imposed by the inabil-
ity to correlate metabolite and microRNA data with
specific proteins. Metabolites are part of biochemical
pathways composed of several reactions that are catal-
yzed by many different enzymes, hence it is not pos-
sible to match one metabolite with a specific enzyme.
Moreover, each microRNA has many target genes and
these genes are regulated by different microRNAs.
Thus, it is not possible to map a single microRNA to
a specific gene. In regard to genomics and epigenet-
ics, we only incorporated those genes that contained
information on the protein/mRNA abundance levels.
In addition, the total set of features was screened
to remove duplicated proteins caused by combining
molecular features from various–omics sources. This
new filtered set reduced the total feature set and was
then subjected to PPI analysis in the context of muscle
invasive bladder cancer.
In order to retrieve protein-protein interaction infor-
mation for the muscle invasive BC associated proteins,
IntAct [46], BioGRID [47], STRING [48] and Reac-
tome [37] were queried. All available human proteins
along with the PPI information were downloaded into
Cytoscape [49] to yield the human interactome based
on experimental evidence. Then, the proteins relative
to MIBC were put on a separate list. MIBC proteins
that had at least one binding partner in the list of MIBC
specific proteins were retained to generate the muscle
invasive BC specific interactome.
To retrieve molecular pathway information for
MIBC, proteins from the muscle invasive BC interac-
tome were subjected to pathway enrichment analysis.
This analysis used two additional sub-applications
from Cytoscape; ClueGO and CluePedia [50–52].
The statistical criterion used in generating molec-
ular pathways included a two-sided hypergeometry
test [51]. Information from KEGG [35] and Reac-
tome [37] databases was used in retrieving significant
pathways associated to MIBC with a Bonferroni
corrected p-value <0.05. In addition, the list of
pathways was inspected manually and redundant
pathway-terms (names) were combined. The fil-
tered list of pathway-terms was then divided into
previously known pathways and novel findings in
the context of muscle invasive bladder carcinoma
[53].
Development of BcCluster database and query
interface
BcCluster database has been built by select-
ing the MySQL database system (http://www.mysql.
com/), to store all comprehensive information regard-
ing published papers, proteins, protein-interactions
and molecular pathways associated specifically to the
muscle invasive phenotype. The query interface for
BcCluster is a web application developed in the Ruby
programming language and using the framework Rails
(http://rubyonrails.org/). This framework was opted
as it provides an advantage to update the BcCluster
database on regular intervals and allow data incor-
poration for newly published articles relevant in BC
research. Supplementary Fig. 1, generated by the Dia
software, illustrates the architecture of the BcCluster
database. The query interface using the Ruby on Rails
framework is detailed in supplementary Fig. 2.
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Fig. 1. Data retrieval flow for the muscle invasive bladder cancer articles and significant molecular features.
RESULTS
Data mining
Database sources (Pubmed, Google scholar and Web
of Science) and omics profiles (GEO and ArrayEx-
press) provided a total of 112 unique references for
manual screening. These references yielded a total of
1,559 molecular features being significantly associ-
ated to muscle invasive bladder cancer (Fig. 1). The
features from individual studies included 113 proteins
from IHC studies, 424 mRNAs and 280 miRNAs (tar-
geted to official gene symbols, by querying miRBase
[54]). 49 genes were derived from DNA mutations
(distinguished into 15 oncogenes and 34 tumor sup-
pressor genes), metabolomics experiments provided
464 molecular features (associated to an enzyme in
gene symbols, by querying HMDB [55]). In addition
79 genes were obtained from DNA methylation studies
and 150 proteins were derived from proteomics stud-
ies. The list of 112 articles collected in this analysis is
provided in Supplementary Table 1.
Systems biology analysis – PPI and pathway
enrichment
The dataset associated with miRNAs and metabo-
lites was not used for pathway enrichment analysis.
This choice was opted due to the inability to cor-
relate metabolite and microRNA data with specific
proteins. In addition, the available bioinformatics tools
(Cytoscape) do not allow efficient integration of these
datasets with other omics data. Subsequently, the
obtained dataset of significant MIBC features was pro-
cessed in order to eliminate duplicate entries. The
new filtered set resulted in a total of 737 proteins that
were then subjected to PPI analysis in the context of
muscle invasive bladder cancer. To obtain all possi-
ble protein interaction information for the 737 muscle
invasive bladder cancer specific proteins, PPI databases
including IntAct, BioGRID, String and Reactome were
queried. Figure 2a, illustrates the steps taken in produc-
ing the muscle invasive bladder cancer interactome. In
the first step, all available PPIs for the human pro-
teome were downloaded into Cytoscape to form the
human interactome. The PPIs relevant to the 737 MIBC
proteins were retrieved from the human interactome
and only proteins with at least one binding partner were
retained (Fig. 2a). This step yielded 435 proteins along
with 4,768 PPIs that were used in the pathway enrich-
ment analysis. 302 proteins that did not have a binding
partner among the full list of 737 relevant to MIBC
were not retained for further analysis.
The 435 proteins that were obtained from the muscle
invasive BC interactome (Fig. 2a) were incorporated
into ClueGO and CluePedia to identify significant
pathways in the context of MIBC. A total of 292 molec-
ular pathways were retrieved in this analysis. This
pathway list was manually screened in order to com-
bine redundant pathway-names. This screening step
reduced the list of pathways to a total of 92 path-
ways that were then distinguished into 75 previously
known in literature and 17 novel pathway findings in
the context to muscle invasive BC (Fig. 2b).
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Fig. 2. a. Generating the muscle invasive bladder cancer interactome. b. Pathway enrichment using the 435 MIBC specific proteins. Each circle
represents a pathway and dots denote proteins. Filled circles represents down-regulation of the pathway in the context of MIBC, while open
circles denotes up-regulation. Pathways are connected through common proteins.
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Fig. 3. Display of molecular features based on study type from the BcCluster database. Molecular features significant in muscle invasive BC are
organized and displayed based on the study type. Users can access these molecular features and retrieve biological information by clicking any
of the listed study types. Additionally, all the results displayed in the application can be downloaded in various file formats (.csv,.txt and.xls).
BcCluster database and web interface
In order to efficiently store and retrieve informa-
tion in regard to the 112 published articles, 1,559
molecular features, 435 proteins, 4,768 PPIs and 92
molecular pathways associated to muscle invasive
bladder carcinoma, a database supported by a web user-
interface was developed. The BcCluster web portal
(http://bccluster.org/biomolecules/study type) lists all
the bladder cancer associated molecular features based
on individual study type and is presented in Fig. 3. The
application allows the user to browse specific omics
traits to gain information regarding features associated
to bladder cancer at different stages and grades of the
disease. In addition the PubMed reference ids for these
retrieved data are also provided and the application
can be queried based on the keywords as described in
Table 1.
For selecting proteins based on literature mined
IHC validated experiments, each muscle invasive BC-
associated protein was evaluated for being a member
of the 92 muscle invasive BC enriched pathways. The
evidence of identified pathways and extracted proteins
involved in muscle invasive BC was assessed based on
the number of individual bladder cancer studies that
described such proteins. The quality of publications
Table 1
Query terms that can be used in BcCluster. Listing the types of
entities that can be used for querying the BcCluster database with a
few examples
Search entity Example of search
Protein coding gene TP53, RB1, ERBB2, etc.
UniProt accession P04637, P06400, P04626, etc.
miRNA id hsa-miR-21, hsa-miR-106a,
hsa-miR-200b, etc.
Metabolite name palmitic acid, Lysine,
S-Adenosylmethionine, etc.
Chromosome/ chr5q32-q34, chr12q13, chr22q11.23
Methylation site
MedLine id (PMID) 24476821, 18840072, etc.
N.B. A combination of query terms can also be used. For e.g. “TP53
and 24476821”, would provide results for the protein-coding gene
TP53 that was reported in the specific article 24476821.
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Fig. 4. Example workflow for Survivin. The query for the protein-coding gene BIRC5 provides a list of publications, the type of studies, the
clinical samples used for the comparison and the relative amount of the gene/mRNA/protein present in these samples. The query term also
provides information on physical protein interactions and molecular pathways since the query term (i.e. protein-coding gene) is part of protein
complexes relevant to muscle invasive BC.
obtained for each protein was assessed by manually
reviewing these articles. Only papers where a direct
relevance for the protein to bladder cancer muscle
invasion was proven were retained. For the entire 92
muscle invasive BC enriched pathways, each relevant
pathway was ranked based on the statistical signifi-
cance (p value). Pathways that appeared at least once
in a bladder cancer study were grouped as literature
known pathways (containing 75 enriched pathways),
while those pathways that were not previously reported
in muscle invasive bladder cancer were categorized as
novel findings (containing 17 enriched pathways).
In-silico hypothesis generation: Survivin as an
example
Previous studies by Shariat SF et al. [56] report sur-
vivin to be a promising biomarker for cancer diagnosis,
prognosis and prediction of response to intravesical or
systemic therapies. Urinary survivin tests in BC have
been shown to perform better than urinary cytology
with a sensitivity of 0.77 (95% confidence interval [CI]
0.75–0.80) and specificity of 0.92 (95% CI 0.90–0.93)
[57–60]. Survivin is a protein involved in the inhibition
of apoptosis and has been reported to control mitotic
progression, in addition to inducing changes in the gene
expression of caspases 3, 7 and 9 that are associated
with cell invasion in BC [61–63]. Hence, we selected
survivin as an example to query BcCluster. The work-
flow of a simple query to the BcCluster database via the
web application is presented in Fig. 4. The search term
used was BIRC5. The results to the search provide a
list of the data available for the molecular feature in
different published studies. The search also displays
other important information such as the type of study
(e.g. IHC, transcriptomics, etc.), the clinical samples
used for the comparison and the relative amount of the
gene/mRNA/protein present in these samples. Addi-
tionally, the application also displays, if available, a
list of the protein-binding partners based on exper-
imental evidence and muscle invasive BC pathways
significantly enriched for the specific query term.
72 A. Bhat et al. / BcCluster: A Bladder Cancer Database at the Molecular Level
Table 2
List of molecular pathways displayed for survivin. Muscle invasive bladder cancer pathways that were enriched for survivin have been listed
and sorted based on the p-value
Enriched pathway p-value MIBC proteins* Pathway source Previous reports in MIBC
Signal transduction 2.46 10−14 153 Reactome:111102 Available [64]
Hippo signaling pathway 4.93 10−09 27 Kegg:04390 Novel
Cell cycle 2.55 10−04 45 Reactome:115566 Available [65]
*Number of proteins from the 435 entries forming the MIBC interactome enriched in the pathway.
Survivin was found to be significantly associated to
3 molecular pathways namely cell cycle, hippo signal-
ing and signal transduction pathways. The 3 molecular
pathways presented in Table 2 are sorted according
to the corrected p-values. Signal transduction (p-value
2.46 10−14) pathway was found to be the most signifi-
cant followed by Hippo signaling (p-value 4.93 10−09),
and cell cycle (p-value 2.55 10−04). From our analysis,
we predict the involvement of survivin to be signif-
icantly associated to Hippo signaling pathway in the
context of muscle invasive bladder cancer.
DISCUSSION
The main aim of this study was to develop a database
specific for invasive bladder cancer. This was achieved
by integrating all possible information publically avail-
able from literature and sequencing platforms, PPIs
and pathway enrichment resources in the context of
MIBC. An example of the database utility is given by
extracting information relevant to survivin in BC.
Aggressive MIBC progresses rapidly to metastatic
diseases and generates high patient mortality [66].
Radical cystectomy combined with systemic cisplatin-
based chemotherapy (either before or after cystectomy)
is the current standard of care for high-risk MIBC [6].
Treatment selection depends particularly on clinico-
pathologic features. Unfortunately current staging
systems are not optimum and yield high rates of clinical
under-staging leading to inadequate treatment [9, 14].
Moreover, distinct molecular subtypes in MIBC have
also been reported including basal, luminal and inter-
estingly “p53-like” that are resistant to chemotherapy
[9]. Understanding the molecular pathophysiology of
muscle-invasive bladder carcinoma and elucidating
the network of pathways involved in invasion could
lead to targeted therapies. In addition, discovery of
specific de-regulated pathways linked to progressive
disease holds the promise of supporting an improved,
biomarker-based risk assessment followed by appro-
priate clinical intervention. High throughput omics
platforms have provided a wealth of information in
describing the molecular status of bladder carcinoma
[11, 24, 67–69]. In order to contribute to the molecular
characterization of invasive BC, we integrated omics
data into a database called BcCluster. A database sys-
tem at the level of networks and pathways was created
in order to provide efficient retrieval of information
for a single molecular feature (such as mutations,
DNA methylation, miRNAs, mRNAs, metabolomics
and IHC). Thus, a comprehensive view on the involve-
ment of a feature in BC invasiveness can be obtained.
Moreover, researchers can access a list of available
high quality data from individual omics platforms (for
e.g. transcriptomics data) and perform systems biol-
ogy analysis (protein-protein interactions and pathway
enrichment) in order to characterize bladder cancer at
the molecular level. In addition, users can download
the data from each study type that is useful to their
research. We are willing to offer all the BcCluster data
in a compressed format to interested users on request.
An application of the database is formulation of sci-
entific hypotheses that can be validated experimentally,
illustrated by the example of survivin. There is ample
experimental evidence supporting the role of survivin
in the context of BC pathology [70–72]. Our approach
in integrating PPI and pathway databases yielded three
significant pathways for survivin (cell cycle, signal
transduction, and hippo signaling). The expression of
survivin positively correlates with the levels of signal
transduction proteins EGFR (Epidermal growth fac-
tor receptor) and VEGFA (Vascular endothelial growth
factor A) in muscle invasive BC [64]. In Reactome, the
term “signal transduction pathway” is described as a
hierarchy of signaling events that elicit changes in cell
state and activity due to the result of extracellular sig-
nals. Some of the types of signal transduction pathways
include, signaling by RTKs, PDGF, NGF, TGF-beta,
JNK and NF-kB, RAF/MAPK and Rho GTPases. In
order to determine which of these signal transduction
pathways were specifically associated to survivin, we
manually queried survivin in the Reactome database
(http://www.reactome.org/). The most prominent path-
way involving survivin was signaling by Rho GTPases.
A transcriptomics study determined that the majority of
the Rho family small GTPases (RhoA, RhoB, RhoC,
Rac1 and Cdc42) are significantly over-expressed in
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BC, hence providing experimental validation of our
in silico prediction [73]. The role of survivin in cell
cycle has previously been reported for MIBC, whereas
hippo signaling is a novel finding. Down-regulation of
survivin is associated with cell cycle arrest and apop-
tosis in BC cell lines [65]. The experimental evidence
confirms our in silico analysis for the involvement of
survivin in BC pathways reported in the literature.
Hippo signaling is a conserved pathway that regulates
organ size and is implicated in cancer development
[74]. Survivin expression was proven to be inversely
correlated with hippo signaling in vascular tumors of
the lungs and liver [75]. The available information indi-
cates that survivin is likely involved in hippo signaling
pathway in the context of BC and experimental vali-
dation for this in silico generated hypothesis could be
attempted.
In summary, data retrieval from the literature and
omics studies resulted in the collection of molec-
ular features associated with muscle invasive BC.
Using these features allowed the generation of the
muscle invasive bladder cancer interactome and path-
ways highly associated to the invasive phenotype.
The pathway enrichment analysis yielded significant
muscle invasive BC pathways that have been previ-
ously reported in literature including PIK3 signaling,
MAPK, focal adhesion, cell cycle, EGFR and ErbB
signaling pathways [11, 14, 76–78]. These studies con-
firm the validity of our systems biology analysis. With
the BcCluster application, we aim towards supporting
a better understanding of complex molecular mecha-
nisms in BC invasion. Similar web-based databases on
individual molecular disorders such as for lung can-
cer [79], breast cancer [80], liver diseases [81], kidney
disorders [82] or specifically for personalized medicine
[83] are currently available. These databases provide
information on features extracted from various omics
studies (ranging from Single Nucleotide Polymor-
phisms, to transcriptomics, miRNAs, metabolomics,
transcriptional binding-factor motifs, PPI networks
and pathways). In addition, the features from the indi-
vidual studies are integrated in a manner to allow
researchers to efficiently retrieve molecular informa-
tion for a specific gene or protein search. In regard
to BC, there are limited database resources that allow
the molecular characterization of the invasive disease.
Publically available BC sources exist, either within
the TCGA portal or in databases focused on miR-
NAs [29–31]. All the molecular features in regard
to mutations, mRNAs, miRNAs and proteins from
the TCGA-MIBC specific database were incorpo-
rated in the BcCluster database. In addition, when
comparing the features stored in HLungDb [79] and
BcCluster, the lung cancer database contains 2,797
molecular features by integrating genes and miR-
NAs, whereas the BcCluster contains 1,559 molecular
features comprising of molecular information rang-
ing from DNA-methylation, DNA-mutations, mRNAs,
proteins (retrieved from proteomics and IHC experi-
ments) and metabolites. In addition, our database also
holds 4,768 PPIs and 92 BC significant pathways
enriched from our systems biology analysis.
In the future, we plan to further expand the BcClus-
ter database by updating our dataset with published
studies and large-scale omics profiles in regular time
intervals. This updated version will allow to refine the
generated muscle invasive protein interactome lead-
ing to a comprehensive molecular characterization and
identification of novel modules in the context of muscle
invasive BC.
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